IMW Meeting Materials 2021

IMW 2021 Program

Wednesday, September, 2021

Precursor Conditions

• Genomic evolution germinal B cell to MGUS/SMM/MM – Brian Walker
• Role of the immune Microenvironment in the journey to MGUS/SMM/MM – Madhav Dhodapkar
• Molecular Timing of Initiation – Niels Weinhold
• Risk factors for MGUS/SMM progression – Vincent Rajkumar
• Management of Smoldering Myeloma – Marivi Mateos
• Should we screen for precursor conditions? – Irene Ghobrial

Molecular dissection of myeloma

• Clonal diversity in Myeloma – Mehmet Samur
• Transcriptome – Jill Corre
• Epigenomic – Wee Joo Chng
• Microbiome – Leif Bergsagel
• Proteomics – Arun Wiita
• Metabolomics – Rafael Fonseca

Multiple Myeloma Diagnosis

• Diagnostic criteria and work-up in 2021 – Shaji Kumar
• How should we define standard and high risk MM in 2022? – Herve Avet-Loiseau
• Role of imaging in diagnosis and response assessment – Elena Zamagni
• Circulating tumor cells and tumor DNA for response assessment – Bruno Paiva
• Mass-spec to monitor the treatment response – Dave Murray
• Assessment of patient frailty and functional status – Alessandra Larocca

Thursday, September 9, 2021

Opening Session

• Novel Therapies for Myeloma – Kenneth Anderson 

Newly diagnosed Multiple Myeloma: Current Treatment Approaches

• Treatment of Newly Diagnosed Myeloma Transplant – Philippe Moreau
• Eligible: what is the optimal induction? ASCT in NDMM transplant eligible –  Michele Cavo
• Consolidation Strategies for MM – Pieter Sonneveld
• Maintenance Strategies for MM – Hartmut Goldschmidt
• Treatment of Newly Diagnosed Myeloma Non-Transplant Eligible– Theirry Facon

Oral Abstracts 

• Overall Survival and Progression-free Survival by Treatment Duration With Daratumumab + Lenalidomide/ Dexamethasone in Transplant-ineligible Newly Diagnosed Multiple Myeloma: Phase 3 MAIA Study – Philippe Moreau
• Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM) –Andrzej Jakubowiak
• CARDAMON:Carfilzomib (K) maintenance following Autologous Stem Cell Transplant (ASCT) or carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation for newly diagnosed (NDTE) multiple myeloma (MM) – Rakesh Popat
• Carfilzomib-Based Induction/Consolidation With or Without Autologous Transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) Maintenance: Efficacy in High-Risk Patients of the FORTE study – Roberto Mina
• Update of Safety and Efficacy of Isatuximab Short-Duration Fixed-Volume Infusion Plus Bortezomib, Lenalidomide, and Dexamethasone Combined Therapy for NDMM Ineligible/With No Immediate Intent for ASCT – Enrique Ocio
• A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma – Vincenza Solli
• Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma – Alexandra Poos
• Identification of High-Risk Multiple Myeloma with a Plasma Cell Leukemia-Like Transcriptomic Profile –  Davine Hofste op Bruinink
• Genome-Wide CRISPR interference Screen Identifies RNA Regulator of Lipogenesis (RROL) as a Leading LncRNA Dependency in Multiple Myeloma – Eugenio Morelli
• Gain(1q) promotes mitochondrial oxidative phosphorylation and suppresses interferon response and tumor immunity in multiple myeloma and other human cancers – Rodger Tiedemann
• Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level – Yuting Yan

Management of relapsed/refractory MM patients

• Approach to first relapse – Meletios-Athanassios Dimopoulos
• Management of triple refractory patients – Bob Orlowski
• Role of immunotherapies for relapsed MM,when and which? – Saad Usmani
• Personalized treatment of relapsed MM: genomics? – Marc Raab

Oral Abstract Sessions

• Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial – Martin Kaiser
• Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/ refractory multiple myeloma (RRMM) – Sagar Lonial
• Newly diagnosed Multiple Myeloma patients with high A. levels of circulating tumor cells are distinguished by increased bone marrow plasma cell proliferation – Cathelijne Fokkema
• Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk – Ruth De Tute
• Treatment pathways for patients with multiple myeloma: a real-life study based on the French National Claim database from 2014 to 2019 –  Aurore Perrot
• Attenuation of T cell cytotoxicity mediated by CD200 expression on multiple myeloma cells – Pooja Shah
  A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence
  in multiple myeloma – Nizar Bahlis
• CRISPR screens with single-cell transcriptome readout reveal potential mechanisms of response to natural killer cell treatment in multiple myeloma – Sara Gandolfi
• The Role of Checkpoint inhibitor PD-1H/VISTA in Multiple Myeloma Bone Disease – Suzanne Lentzsch
• BCMA-specific ADC MEDI2228 and Daratumumab induce synergistic myeloma cytotoxicity via enhanced IFN-driven innate immune responses and expression of CD38 and NKG2D ligands – Yu-Tzu Tai
• Monoallelic Deletion of BCMA Locus is a Frequent Feature in MM and is Associated with Increased
  Genomic Loss – Mehmet Samur

Friday, September 10, 2021

Opening Session 

• Future of myeloma treatment – Jesus San Miguel

IMS/EHA SYMPOSIUM: Immune Therapies: A game changer for Hematological Malignancies

• CART
• Other Immune Approaches – John Gribben

Oral Abstract Sessions

• Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1–3 prior lines of therapy: Initial results from CARTITUDE-2 – Adam Cohen
• Updated results from CARTITUDE-1: Ciltacabtageneautoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM) – Sundar Jagannath
• Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study – Niels van de Donk
• MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM) – Bhagirathbhai Dholaria
• Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa –  Larry Anderson
• FAM46C-Dependent Tuning of Endoplasmic Reticulum Capacity in Multiple Myeloma – Enrico Milan
• Bone marrow adipocytes induce metabolic reprogramming of multiple myeloma cells – Cristina Panaroni
• Combined targeting of distinct c-Myc and JunB transcriptional programs induces synergistic anti-myeloma activity – Judith Lind
• Circular RNA protein tyrosine kinase 2 promotes cell proliferation, migration and suppresses apoptosis via activating microRNA-638 mediated MEK/ERK, WNT/β-catenin signaling pathways in myeloma – Fan Zhou
• Targeting GCK in RAS-mutant multiple myeloma offer a promising therapeutic approach – Suzanne Lentzsch
• Loss-of-function of GABARAP drives tumor resistance to bortezomib-induced immunogenic cell death in multiple myeloma – Annamaria Gulla

Other Plasma Cell Disorders

• Current strategies for AL patients – Giovanni Palladini
• What are the novel approaches in WM? – Steve Treon
• Monoclonal gammopathy of clinical significance – Joan Blade
• Monclonal gammopathy of renal significance – Nelson Leung

Oral Abstracts

• Evaluating the Impact of Cytogenetic Abnormalities on Treatment Outcomes in Patients with AL Amyloidosis: Subanalyses From the ANDROMEDA Study – Shaji Kumar
• Minimally invasive profiling of tumor and immune cells to stratify risk in smoldering multiple myeloma (SMM): the iMMunocell study – Rosalinda Termini
• Graded Renal Response Criteria and Revised Renal Progression Criteria for Light chain (AL) Amyloidosis – Eli Muchtar
• Assessing the prognostic utility of the Mayo 2018 IMWG 2020 smoldering multiple myeloma risk stratification scores applied post diagnosisand – Alyssa Visram
• Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival – Eli Muchtar
• Distinct immunoglobulin heavy-chain variable gene repertoire and its clinical relevance in Waldenström
  macroglobulinemia/lymphoplasmacytic lymphoma –Yuting Yan
• Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström Macroglobulinemia – Sabrin Tahri
• Epithelial-mesenchymal-transition regulated by Junctional Adhesion Molecule-A (JAM-A) associates with aggressive extramedullary multiple myeloma disease – Antonio Solimando
• Targeting Free Light Chain Secretion via Botulinum Neurotoxin is a Novel Therapeutic Strategy in AL amyloidosis by Inducing a Terminal Unfolded Protein Response – Maria Moscvin
• Progression and probability of progression are driven by different genomic features in precursor conditions in myeloma – Anil Aktas-Samur
• Anti-CD38 nanobodies as theranostic agents for multiple myeloma – Elodie Duray

Hot Topics in Myeloma: Covid-19 in MM: what we have learnt?

• COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia – Andrew Branagan
• COVID-19 infection in multiple myeloma patients retrospective analysis of 371 Czech patients – Jakub Radocha
• Plasma cell disorder patients are left vulnerable after one dose of the BNT162b2 mRNA or the ChAdOx-nCOV-19 COVID-19 vaccines – Wei Yee Chan
• Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment – Oliver Van Oekelen
• Poor Post-vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and Anti-CD38 Treatment – Susanne Ghandili
• What have we leaned? – Evangelos Terpos

Saturday, September 11, 2021

Oral Abstract Sessions

• OCEAN (OP-103): A Phase 3, Randomized, Global, Head-to-Head Comparison Study of Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) – Fredrik Schjesvold
• Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Treatment Duration and Cessation in Newly Diagnosed Multiple Myeloma (NDMM) – Luciano J. Costa
• Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial – Prashant Kapoor
• Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy – Oliver Van Oekelen
• Single-cell RNA-sequencing identifies immune biomarkers of response to immunotherapy in patients with high-risk Smoldering Myeloma –  Romanos Sklavenitis-Pistofidis
• Gain and Amplification of 1q Induce Transcriptome Deregulation and Worsen the Outcome of Newly Diagnosed Multiple Myeloma Patients – Mattia D’Agostino
• A machine learning model based on tumor and immune biomarkers to predict undetectable measurable residual disease (MRD) in transplant-eligible multiple myeloma (MM) – Camila Guerrero
• Temporal-weight estimation of the copy number alterations of 1384 multiple myeloma patients defines an ancestrality index impacting patient survival – Andrea Poletti
• Predictive relevance of sustained MRD negativity and of early loss of MRD negativity during maintenance therapy after transplant in newly diagnosed Multiple Myeloma patients – Angelo Belotti
• Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading – Marina Martello
• Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: Results of the iTIMM trial – Martin Kaiser

Great Debates in Myeloma

• Should every transplant eligible NDMM patient receive a transplant? Sergio Giralt/Morie Gertz
• Are we ready for MRD-guided therapy? Sundar Jagannath/Ola Landgren
• Is stratification based on genomics ready for primetime? Gareth Morgan/Faith Davies
• Which is the best immune approach to replace ASCT? Hermann Einsele/Parameswaran Hari
• Can we give our patient treatment free intervals? Luciano Costa/ Phil McCarthy
• Is there a role for alkylator in MM? Donna Reece/Jeff Wolf

Supportive care management

• Management of renal failure – Jean-Paul Fermand
• Approaches to bone health – Evangelos Terpos
• Management of infections – Michel Delforge
• Toxicity management – Elizabeth O’Donnell
• Vaccinations in myeloma including covid-19 – Heinz Ludwig

Immune Therapies

• Mechanism of resistance to CAR-T cells and bispecifics – Yi Lin
• How to improve the efficacy of CAR-T cells and bi-specifics? –  Michael Hudecek
• Allo-CAR-T cels – Roman Hajek
• CAR- NK cells – Adam Cohen
• Vaccination Therapies for Myeloma – David Avigan

Clinical Trials in Progress

• North America – Jonathan Kaufman
• Europe – Xavier Leleu
• South America – Vania Hungria
• Asia – Jeffrey Huang
• Australia – Hang Quach